Humana (NYSE:HUM) issued a sobering outlook for 2026, projecting that a significant drop in government bonus payments will weigh on its bottom line even as the insurer sees a massive rebound in customer acquisition.
Madrigal Pharmaceuticals (NASDAQ:MDGL) is doubling down on its dominance of the liver-disease market, announcing an expansive partnership with Ribo to develop next-generation gene-silencing therapies.
IRADIMED (NASDAQ:IRMD), a leader in MRI-compatible medical devices, reported record financial results for the fourth quarter and full year ended December 31, 2025.
Quest Diagnostics (NYSE:DGX) delivered a robust fourth-quarter beat on Tuesday, February 10, 2026, as the company’s pivot toward high-growth hospital partnerships and consumer wellness testing pushed annual revenue past the $11 billion milestone.
Incyte (NASDAQ:INCY) delivered a robust finish to 2025 on Tuesday, February 10, 2026, marking its first year crossing the $5 billion revenue threshold.
InMode (NASDAQ:INMD), a leading provider of innovative aesthetic medical technologies, reported financial results for the fourth quarter and full year ended December 31, 2025.
CVS Health (NYSE:CVS) reported on Tuesday, February 10, 2026, that it has become the first pure-play healthcare company to surpass $400 billion in annual revenue, even as a series of heavy one-time charges masked the underlying strength of its Aetna and Caremark units.
Zimmer Biomet Holdings (NYSE:ZBH) reported fourth-quarter results on Tuesday, February 10, 2026, that exceeded Wall Street expectations, though the medical device giant’s shares remained under pressure following a "cautious" outlook for the coming fiscal year.
Oscar Health (NYSE:OSCR) reported a complex finish to 2025 on Tuesday, February 10, 2026, revealing a widening quarterly loss even as it achieved a historic membership milestone.
Organigram Global (NASDAQ:OGI) reported a dominant start to its fiscal 2026 on Tuesday, posting a 49% year-over-year surge in net revenue to $63.5 million.
Koninklijke Philips (NYSE:PHG) reported a return to profitability in its fourth quarter, bolstered by a 7% rise in comparable sales and the successful rollout of AI-driven medical imaging systems.
AstraZeneca (NASDAQ:AZN) reported fourth-quarter and full-year 2025 results on Tuesday that failed to meet Wall Street’s expectations, as a surge in operating costs for its expanding drug pipeline dampened the impact of double-digit sales growth in its oncology division.
